The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
Open accessAbstract
Activating mutations in BRAF kinase are common in melanomas. Clinical trials with PLX4032, the mutant-BRAF inhibitor, show promising preliminary results in patients selected for the presence of V600E mutation. However, activating V600K mutation is the other most common mutation, yet patients with this variant are currently excluded from the PLX4032 trials. Here we present evidence that a patient bearing the BRAF V600K mutation responded remarkably to PLX4032, suggesting that clinical trials should include all patients with activating BRAF V600E/K mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Halaban, R., Zhang, W., Bacchiocchi, A., Cheng, E., Parisi, F., Ariyan, S., Krauthammer, M., McCusker, J. P., Kluger, Y., & Sznol, M. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00685.x · Cited by 326
Self-citationBRAF and NRAS mutations in melanoma and melanocytic nevi
Poynter, J. N., Elder, J. T., Fullen, D. R., Nair, R. P., Soengas, M. S., Johnson, T. M., Redman, B., Thomas, N. E., & Gruber, S. B. (2006) · Melanoma Research · doi:10.1097/01.cmr.0000222600.73179.f3 · Cited by 245
Willmore-Payne, C., Holden, J. A., Tripp, S., & Layfield, L. J. (2005) · Human Pathology · doi:10.1016/j.humpath.2005.03.015 · Cited by 230
Flaherty, K., Puzanov, I., Sosman, J., Kim, K., Ribas, A., McArthur, G., Lee, R. J., Grippo, J. F., Nolop, K., & Chapman, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.9000 · Cited by 229
Sala, E., Mologni, L., Truffa, S., Gaetano, C., Bollag, G. E., & Gambacorti-Passerini, C. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2001 · Cited by 188
Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response
Pratilas, C. A., & Solit, D. B. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3064 · Cited by 183
Uribe, P., Wistuba, I. I., & González, S. (2003) · American Journal of Dermatopathology · doi:10.1097/00000372-200310000-00001 · Cited by 142
Ugurel, S., Thirumaran, R. K., Bloethner, S., Gast, A., Sucker, A., Mueller-Berghaus, J., Rittgen, W., Hemminki, K., Becker, J. C., Kumar, R., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000236 · Cited by 134
Hay, R. W., Macrae, E. R., Barber, D., Khalil, M., & Demetrick, D. J. (2007) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2007-131-1361-bmimla · Cited by 22
Cited by
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,831
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Long, G. V., Menzies, A. M., Nagrial, A. M., Haydu, L. E., Hamilton, A. L., Mann, G. J., Hughes, T. M., Thompson, J. F., Scolyer, R. A., & Kefford, R. F. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.4327 · Cited by 1,042
The role of BRAF V600 mutation in melanoma
Ascierto, P. A., Kirkwood, J. M., Grob, J.-J., Simeone, E., Grimaldi, A. M., Maio, M., Palmieri, G., Testori, A., Marincola, F. M., & Mozzillo, N. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-85 · Cited by 801
Cutaneous melanoma: From pathogenesis to therapy (Review)
Leonardi, G., Falzone, L., Salemi, R., Zangh�, A., Spandidos, D., Mccubrey, J., Candido, S., & Libra, M. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4287 · Cited by 588
Signal pathways of melanoma and targeted therapy
Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 379
Metadata
- Authors
- Rubinstein, J. C., Sznol, M., Pavlick, A. C., Ariyan, S., Cheng, E., Bacchiocchi, A., Kluger, H. M., Narayan, D., & Halaban, R.
- Venue
- Journal of Translational Medicine
- Published
- 2010-07-14
- Volume
- 8
- Issue
- 1
- Pages
- 67-67
- ISSN
- 1479-5876 (ISSN-L)
- OpenAlex
- W2121377606
- Cited by
- 254
- References
- 9
- FWCI
- 9.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. https://app.cochat.ai/papers/10.1186/1479-5876-8-67
- The paper
- Rubinstein, J. C., Sznol, M., Pavlick, A. C., Ariyan, S., Cheng, E., Bacchiocchi, A., Kluger, H. M., Narayan, D., & Halaban, R. (2010). Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. Journal of Translational Medicine. https://doi.org/10.1186/1479-5876-8-67
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.